Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome - After intranasal exposure to andes virus

Monica Ogg, Colleen Jonsson, Jeremy V. Camp, Jay W. Hooper

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Andes virus, ANDV, harbored by wild rodents, causes the highly lethal hantavirus pulmonary syndrome (HPS) upon transmission to humans resulting in death in 30% to 50% of the cases. As there is no treatment for this disease, we systematically tested the efficacy of ribavirin in vitro and in an animal model. In vitro assays confirmed antiviral activity and determined that the most effective doses were 40 μg/mL and above. We tested three different concentrations of ribavirin for their capability to prevent HPS in the ANDV hamster model following an intranasal challenge. While the highest level of ribavirin (200 mg/kg) was toxic to the hamster, both the middle (100 mg/kg) and the lowest concentration (50 mg/kg) prevented HPS in hamsters without toxicity. Specifically, 8 of 8 hamsters survived intranasal challenge for both of those groups whereas 7 of 8 PBS control-treated animals developed lethal HPS. Further, we report that administration of ribavirin at 50 mg/kg/day starting on days 6, 8, 10, or 12 post-infection resulted in significant protection against HPS in all groups. Administration of ribavirin at 14 days post-infection also provided a significant level of protection against lethal HPS. These data provide in vivo evidence supporting the potential use of ribavirin as a post-exposure treatment to prevent HPS after exposure by the respiratory route.

Original languageEnglish (US)
Pages (from-to)2704-2720
Number of pages17
JournalViruses
Volume5
Issue number11
DOIs
StatePublished - Nov 8 2013

Fingerprint

Hantavirus Pulmonary Syndrome
Hantavirus
Ribavirin
Mesocricetus
Cricetinae
Poisons
Infection
Antiviral Agents
Rodentia
Animal Models

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Virology

Cite this

Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome - After intranasal exposure to andes virus. / Ogg, Monica; Jonsson, Colleen; Camp, Jeremy V.; Hooper, Jay W.

In: Viruses, Vol. 5, No. 11, 08.11.2013, p. 2704-2720.

Research output: Contribution to journalArticle

@article{93d2347ea38a4d98bb0cd84ae84c50f1,
title = "Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome - After intranasal exposure to andes virus",
abstract = "Andes virus, ANDV, harbored by wild rodents, causes the highly lethal hantavirus pulmonary syndrome (HPS) upon transmission to humans resulting in death in 30{\%} to 50{\%} of the cases. As there is no treatment for this disease, we systematically tested the efficacy of ribavirin in vitro and in an animal model. In vitro assays confirmed antiviral activity and determined that the most effective doses were 40 μg/mL and above. We tested three different concentrations of ribavirin for their capability to prevent HPS in the ANDV hamster model following an intranasal challenge. While the highest level of ribavirin (200 mg/kg) was toxic to the hamster, both the middle (100 mg/kg) and the lowest concentration (50 mg/kg) prevented HPS in hamsters without toxicity. Specifically, 8 of 8 hamsters survived intranasal challenge for both of those groups whereas 7 of 8 PBS control-treated animals developed lethal HPS. Further, we report that administration of ribavirin at 50 mg/kg/day starting on days 6, 8, 10, or 12 post-infection resulted in significant protection against HPS in all groups. Administration of ribavirin at 14 days post-infection also provided a significant level of protection against lethal HPS. These data provide in vivo evidence supporting the potential use of ribavirin as a post-exposure treatment to prevent HPS after exposure by the respiratory route.",
author = "Monica Ogg and Colleen Jonsson and Camp, {Jeremy V.} and Hooper, {Jay W.}",
year = "2013",
month = "11",
day = "8",
doi = "10.3390/v5112704",
language = "English (US)",
volume = "5",
pages = "2704--2720",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome - After intranasal exposure to andes virus

AU - Ogg, Monica

AU - Jonsson, Colleen

AU - Camp, Jeremy V.

AU - Hooper, Jay W.

PY - 2013/11/8

Y1 - 2013/11/8

N2 - Andes virus, ANDV, harbored by wild rodents, causes the highly lethal hantavirus pulmonary syndrome (HPS) upon transmission to humans resulting in death in 30% to 50% of the cases. As there is no treatment for this disease, we systematically tested the efficacy of ribavirin in vitro and in an animal model. In vitro assays confirmed antiviral activity and determined that the most effective doses were 40 μg/mL and above. We tested three different concentrations of ribavirin for their capability to prevent HPS in the ANDV hamster model following an intranasal challenge. While the highest level of ribavirin (200 mg/kg) was toxic to the hamster, both the middle (100 mg/kg) and the lowest concentration (50 mg/kg) prevented HPS in hamsters without toxicity. Specifically, 8 of 8 hamsters survived intranasal challenge for both of those groups whereas 7 of 8 PBS control-treated animals developed lethal HPS. Further, we report that administration of ribavirin at 50 mg/kg/day starting on days 6, 8, 10, or 12 post-infection resulted in significant protection against HPS in all groups. Administration of ribavirin at 14 days post-infection also provided a significant level of protection against lethal HPS. These data provide in vivo evidence supporting the potential use of ribavirin as a post-exposure treatment to prevent HPS after exposure by the respiratory route.

AB - Andes virus, ANDV, harbored by wild rodents, causes the highly lethal hantavirus pulmonary syndrome (HPS) upon transmission to humans resulting in death in 30% to 50% of the cases. As there is no treatment for this disease, we systematically tested the efficacy of ribavirin in vitro and in an animal model. In vitro assays confirmed antiviral activity and determined that the most effective doses were 40 μg/mL and above. We tested three different concentrations of ribavirin for their capability to prevent HPS in the ANDV hamster model following an intranasal challenge. While the highest level of ribavirin (200 mg/kg) was toxic to the hamster, both the middle (100 mg/kg) and the lowest concentration (50 mg/kg) prevented HPS in hamsters without toxicity. Specifically, 8 of 8 hamsters survived intranasal challenge for both of those groups whereas 7 of 8 PBS control-treated animals developed lethal HPS. Further, we report that administration of ribavirin at 50 mg/kg/day starting on days 6, 8, 10, or 12 post-infection resulted in significant protection against HPS in all groups. Administration of ribavirin at 14 days post-infection also provided a significant level of protection against lethal HPS. These data provide in vivo evidence supporting the potential use of ribavirin as a post-exposure treatment to prevent HPS after exposure by the respiratory route.

UR - http://www.scopus.com/inward/record.url?scp=84887344819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887344819&partnerID=8YFLogxK

U2 - 10.3390/v5112704

DO - 10.3390/v5112704

M3 - Article

VL - 5

SP - 2704

EP - 2720

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 11

ER -